Supplemental Figure 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Q: What type of study is this?

This is a Quantitative Study study.

Howard L. Li; Soren Charmsaz; Mari Nakazawa; Stephanie Alden; Madelena Brancati; James M. Leatherman; Ervin Griffin; Hua‐Ling Tsai; Nicole Groß; Christopher J. Thoburn; Alexei Hernandez; Erin M. Coyne; Sarah M. Shin; Royce P. Lee; Evan J. Lipson; Burles A. Johnson; Aliyah Pabani; Yasser Ged; Marina Baretti; Julie R. Brahmer; Jean Hoffman‐Censits; Tanguy Y. Seiwert; Daniel J. Zabransky; Jennifer N. Durham; Elizabeth M. Jaffee; G. Scott Chandler; Brittany L. Adler; Won Jin Ho; Chester Kao; Mark Yarchoan

doi:10.1158/2767-9764.30256044

Key Points

Th1 cytokines, including IFN-gamma and IL-12, increase significantly in patients with immune checkpoint inhibitor-related fatigue.
Patients without disease progression exhibit these elevated cytokine levels when compared to those without related fatigue, highlighting a key relationship.
The Wilcoxon Rank-Sum Test confirms statistically significant differences in cytokine levels (p<0.05) after excluding early progressors.
These findings suggest potential immune mechanisms underlying fatigue experienced by cancer patients on immune checkpoint inhibitor therapy.

Implication

Analysis shows increased Th1 cytokines in patients with immune checkpoint inhibitor-related fatigue, indicating significant immune activation.

Abstract

Supplemental Figure 1. Early-on-treatment Log2 Fold Change Differences After Excluding Progressors. After excluding patients who had disease progression within 2 months of early-on-treatment fatigue inquiry, Th1 cytokines are still significantly increased in patients with ICI-related fatigue compared to no ICI-related fatigue, evidenced by (A) IFN-gamma and (B) IL-12. Wilcoxon Rank-Sum Test, *p<0.05.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a217d1 https://doi.org/10.1158/2767-9764.30256044

View Full Paper

Ask AI

Bookmark

Share

Supplemental Figure 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplemental Figure 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading